WMT AG

Corporate description / mission:
WMT targets the Warburg metabolism of advanced cancers ("Warburg Metabolism Therapeutics").
Their anti-Warburg warheads induce an artificial starvation/ hibernation of the cell, i.e. a broad shutdown of energy metabolism but w/o killing the cell. This allows for a certain therapeutic window by not affecting normal cells but "cooling down" fast growing, highly glycolytic cancer cells.
Using this mechansism they will target certain late stage solid cancers which are predisposed to their type of treatment (gynecological & lung cancers (NSCLC and SCLC), others).

Their goal is to develop an own drug candidate through a phase I/II early clinical study thereby establishing a dosing regimen and validating biomarkers of predisposition and therapeutic response.